Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
per week
for first 24 weeks

Enjoy unlimited digital access
Cancel Anytime
Enjoy Unlimited Digital Access
Canada’s most-awarded
newsroom for a reason
Stay informed for a
lot less, cancel anytime
“Exemplary reporting on
COVID-19” – Herman L
per week
for 24 weeks
Get full access to
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(}function setPanelState(o){dom.root.classList[o?"add":"remove"](,dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

U.S. President Donald Trump proved once again this week that he possesses an uncanny ability to yank the mainstream media’s chain, when he expressed his desire to end the social-distancing measures employed to stop the spread of COVID-19 by Easter Sunday.

By now, you’d think the U.S. media would be more discerning in how it interprets the President’s comments on any given topic. Mr. Trump speaks through his hat like a used-car salesman, always overselling this or that aspect of his administration with over-the-top superlatives. He constantly evokes hypotheticals that would be political quicksand for any conventional politician. And nothing seems more hypothetical at this point than the suggestion that the United States will have conquered its growing coronavirus epidemic by mid-April.

So, that’s how I took the March 22 tweet, in which Mr. Trump insisted “we cannot let the cure be worse than the problem itself.” I imagined him sitting in the White House last Sunday, growing more agitated by the second as commentators on U.S. cable news evoked the economic meltdown the U.S. is experiencing as it seeks to flatten the coronavirus curve.

Story continues below advertisement

For a man who measures his presidency in the ups (and lately downs) of the stock market, it must have been excruciating. Couple that with his disdain for the mainstream media and you just knew he was going to get mischievous. Besides, no one is better at distracting the media’s attention from the real news than Mr. Trump. Yawn, another Trump tempest in a teapot.

As with everything he says, you can’t hold him to it. The man has no compunction. But that is not the same thing as saying he acts rashly. To those who jumped to conclusions about his intentions regarding the lifting of social distancing in two weeks time, I’d say: “Take a pill.”

Speaking of drugs, Mr. Trump also jumped the gun by tweeting about an unproven remedy for COVID-19, hydroxychloroquine, as potentially being “one of the biggest game changers in the history of medicine.” That one did serious damage. It raised false hopes among some desperate people, who reportedly ingested the drug or products that contain it, with devastating consequences. It also undermined serious efforts to examine the drug’s potential.

Medical staff at the IHU Mediterranee Infection Institute in Marseille, France, display packets of Nivaquine on Feb. 26, 2020.


It was natural for the U.S. government’s top infectious-diseases specialist, Anthony Fauci, to push back against Mr. Trump’s assertions about hydroxychloroquine and a molecularly similar drug, the anti-malarial treatment chloroquine, noting that evidence of their effectiveness in treating COVID-19 had been only “anecdotal.” Months-long clinical trials are still needed.

Still, it would be wrong to dismiss chloroquine’s potential as a COVID-19 treatment simply because Mr. Trump likes its odds. The article cited in touting the drug, published in the International Journal of Antimicrobial Agents, has sparked serious debate around the world. Its principal author, Didier Raoult of Aix-Marseille Université in France, has long challenged the medical establishment in his country. And he’s often been right.

French professor Didier Raoult, seen here on Feb. 26, 2020, published a non-peer-reviewed study touting the potential of chloroquine as a treatment for COVID-19.


Dr. Raoult’s non-peer-reviewed study, as well as preliminary research conducted in China, quickly prompted French authorities to approve clinical trials on the drug. French President Emmanuel Macron’s government also approved chloroquine as a treatment for severe COVID-19 cases in a hospital setting, under strict supervision by a group of doctors.

Nice Mayor Christian Estrosi, who said his COVID-19 symptoms all but disappeared after taking hydroxychloroquine in combination with the antibiotic drug azithromycin, as prescribed by Dr. Raoult, has called on Mr. Macron’s government to go much further.

Story continues below advertisement

“Chloroquine is perhaps one of the most prescribed drugs in the world,” Dr. Raoult said in a summary of his study, noting that it has been a staple anti-malarial treatment for European travellers to Africa, and Africans themselves, for decades. Until January, chloroquine was available over the counter in France. Hydroxychloroquine has been prescribed for years globally to treat autoimmune diseases such as rheumatoid arthritis and lupus.

“It is difficult to find a product that currently has a better-established safety profile than chloroquine,” Dr. Raoult’s study asserts. “Furthermore, its cost is negligible. Hence, its possible use both in prophylaxis in people exposed to the novel coronavirus and as a curative treatment will probably be promptly evaluated by our Chinese colleagues. If clinical data confirm the biological results, the novel coronavirus-associated disease will have become one of the simplest and cheapest to treat and prevent among infectious respiratory diseases.”

That remains a big if. Health Authorities in Canada should hold off approving chloroquine or hydroxychloroquine for broad use as a treatment against COVID-19, until proper clinical trials determine its effectiveness and prove it can be used safely. They should, however, consider allowing for their use on a compassionate basis now for the most severe COVID-19 cases.

The only downside is that, if it works, Mr. Trump will never let anyone forget it.

Keep your Opinions sharp and informed. Get the Opinion newsletter. Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to If you want to write a letter to the editor, please forward to

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies